FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136534> ?p ?o ?g. }

• W4324136534 endingPage "689" @default.
• W4324136534 startingPage "689" @default.
• W4324136534 abstract "689 Background: The treatment landscape of metastatic renal cell carcinoma (mRCC) has evolved over recent years with several systemic anti-cancer therapies (SACT) licensed across different lines of treatment. There is ongoing discussion amongst oncology professionals about how best to optimise treatments in terms of sequencing to maximise the potential number of lines or to give the best treatments first. A previous south-west UK audit was completed in 2021 reviewing the drop off rates across 5 UK sites identifying that 69% of patients were able to receive second line therapy and 34% were able to receive third line therapy. Methods: In this study we conducted retrospective analysis of all patients who commenced treatment with SACT for mRCC between 1st January 2018 and 30th June 2021 in 18 centres across the 4 nations of the United Kingdom. All NHS reimbursed treatment options including the COVID interim treatment guideline options were included. Patients who received SACT as part of a clinical trial were also included. Patients who continued on their respective lines of treatment were censored. We also identified patients who had been on a period of active surveillance before staring SACT in this cohort. Results: 1549 patients (71% male: 29% female) were included. IMDC subgroup patients included 21.6% favourable, 52.3% intermediate, 25.1% poor and 1% unavailable. 9.1% of patients had been on active surveillance before starting SACT – defined as a period of longer than 3 months from mRCC diagnosis to starting SACT. Of those patients that started SACT 60.5% of eligible patients had 2 nd line therapy, 25.3% had 3 rd line, 7.2% received 4 th line therapy and only 1% had 5 th line therapy. In the 1 st line setting 58.9% received single agent VEGF TKI, 24.5% received combination ipilimumab and nivolumab (IO-IO) immunotherapy, 14 % received IO/ VEGF TKI combination and 2.6% received other/trial treatment. The single agent VEGF TKI ratio for 1 st line SACT declined year by year with rising IO-IO and IO/VEGF TKI combination ratios seen. In the second- and third-line settings cabozantinib (33.2% 2nd line and 44.4% 3 rd line) and nivolumab (32.8% 2 nd line and 22.6% 3 rd line) were the most common options. Disease progression or death was the most common cause of SACT discontinuation amounting to 57.4%, 62.5% and 79% of SACT cessation in the 1 st , 2 nd and 3 rd lines respectively. Treatment toxicity SACT discontinuation rates were 22.8%, 21.4% and 10.9% for 1 st , 2 nd and 3 rd lines respectively. Conclusions: These results suggest that with more treatment options available, including combination/immunotherapy therapies, more patients are able to receive second- and third-line therapies. That said there remains significant drop off rates mostly driven by disease progression that would support the use of our most effective therapies in the upfront setting." @default.
• W4324136534 created "2023-03-15" @default.
• W4324136534 creator A5000135498 @default.
• W4324136534 creator A5002219984 @default.
• W4324136534 creator A5010862484 @default.
• W4324136534 creator A5029941351 @default.
• W4324136534 creator A5029942908 @default.
• W4324136534 creator A5032681658 @default.
• W4324136534 creator A5034586479 @default.
• W4324136534 creator A5036443989 @default.
• W4324136534 creator A5041384468 @default.
• W4324136534 creator A5041959821 @default.
• W4324136534 creator A5045265012 @default.
• W4324136534 creator A5048579610 @default.
• W4324136534 creator A5048703191 @default.
• W4324136534 creator A5051731874 @default.
• W4324136534 creator A5051739832 @default.
• W4324136534 creator A5056258844 @default.
• W4324136534 creator A5068722061 @default.
• W4324136534 creator A5070417221 @default.
• W4324136534 creator A5078697919 @default.
• W4324136534 creator A5080891568 @default.
• W4324136534 date "2023-02-20" @default.
• W4324136534 modified "2023-10-16" @default.
• W4324136534 title "Multi-centre review of systemic anti-cancer prescribing patterns and treatment drop off rates in the United Kingdom 2018-2021." @default.
• W4324136534 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.689" @default.
• W4324136534 hasPublicationYear "2023" @default.
• W4324136534 type Work @default.
• W4324136534 citedByCount "0" @default.
• W4324136534 crossrefType "journal-article" @default.
• W4324136534 hasAuthorship W4324136534A5000135498 @default.
• W4324136534 hasAuthorship W4324136534A5002219984 @default.
• W4324136534 hasAuthorship W4324136534A5010862484 @default.
• W4324136534 hasAuthorship W4324136534A5029941351 @default.
• W4324136534 hasAuthorship W4324136534A5029942908 @default.
• W4324136534 hasAuthorship W4324136534A5032681658 @default.
• W4324136534 hasAuthorship W4324136534A5034586479 @default.
• W4324136534 hasAuthorship W4324136534A5036443989 @default.
• W4324136534 hasAuthorship W4324136534A5041384468 @default.
• W4324136534 hasAuthorship W4324136534A5041959821 @default.
• W4324136534 hasAuthorship W4324136534A5045265012 @default.
• W4324136534 hasAuthorship W4324136534A5048579610 @default.
• W4324136534 hasAuthorship W4324136534A5048703191 @default.
• W4324136534 hasAuthorship W4324136534A5051731874 @default.
• W4324136534 hasAuthorship W4324136534A5051739832 @default.
• W4324136534 hasAuthorship W4324136534A5056258844 @default.
• W4324136534 hasAuthorship W4324136534A5068722061 @default.
• W4324136534 hasAuthorship W4324136534A5070417221 @default.
• W4324136534 hasAuthorship W4324136534A5078697919 @default.
• W4324136534 hasAuthorship W4324136534A5080891568 @default.
• W4324136534 hasConcept C121608353 @default.
• W4324136534 hasConcept C126322002 @default.
• W4324136534 hasConcept C142724271 @default.
• W4324136534 hasConcept C162324750 @default.
• W4324136534 hasConcept C185926286 @default.
• W4324136534 hasConcept C187736073 @default.
• W4324136534 hasConcept C199521495 @default.
• W4324136534 hasConcept C2780182762 @default.
• W4324136534 hasConcept C530470458 @default.
• W4324136534 hasConcept C71924100 @default.
• W4324136534 hasConcept C72563966 @default.
• W4324136534 hasConceptScore W4324136534C121608353 @default.
• W4324136534 hasConceptScore W4324136534C126322002 @default.
• W4324136534 hasConceptScore W4324136534C142724271 @default.
• W4324136534 hasConceptScore W4324136534C162324750 @default.
• W4324136534 hasConceptScore W4324136534C185926286 @default.
• W4324136534 hasConceptScore W4324136534C187736073 @default.
• W4324136534 hasConceptScore W4324136534C199521495 @default.
• W4324136534 hasConceptScore W4324136534C2780182762 @default.
• W4324136534 hasConceptScore W4324136534C530470458 @default.
• W4324136534 hasConceptScore W4324136534C71924100 @default.
• W4324136534 hasConceptScore W4324136534C72563966 @default.
• W4324136534 hasIssue "6_suppl" @default.
• W4324136534 hasLocation W43241365341 @default.
• W4324136534 hasOpenAccess W4324136534 @default.
• W4324136534 hasPrimaryLocation W43241365341 @default.
• W4324136534 hasRelatedWork W1969823368 @default.
• W4324136534 hasRelatedWork W2041796348 @default.
• W4324136534 hasRelatedWork W2071535500 @default.
• W4324136534 hasRelatedWork W2315085516 @default.
• W4324136534 hasRelatedWork W2324226934 @default.
• W4324136534 hasRelatedWork W2603773853 @default.
• W4324136534 hasRelatedWork W4200529218 @default.
• W4324136534 hasRelatedWork W4231870048 @default.
• W4324136534 hasRelatedWork W4249487090 @default.
• W4324136534 hasRelatedWork W3086789076 @default.
• W4324136534 hasVolume "41" @default.
• W4324136534 isParatext "false" @default.
• W4324136534 isRetracted "false" @default.
• W4324136534 workType "article" @default.